The S-Connect study: Results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 5, Issue 6, 2013, Pages

  Shah, Raj C ^a   Kamphuis, Patrick J ^b   Leurgans, Sue ^a   Swinkels, Sophie H ^b   Sadowsky, Carl H ^c   Bongers, Anke ^b   Rappaport, Stephen A ^d   Quinn, Joseph F ^e   Wieggers, Rico L ^b   Scheltens, Philip ^f   Bennett, David A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Nutricia Nederland   (Netherlands)

^c UNIVERSITY OF NORTH FLORIDA   (United States)

^d Agewell Health   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; NUTRACEUTICAL; SOUVENAID; UNCLASSIFIED DRUG;

ADD ON THERAPY; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BLOOD SAFETY; BRAIN HEMORRHAGE; CLINICAL DEMENTIA RATING; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 84891795217     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt224     Document Type: Article

References (29)

1. Alzheimer's Disease International, World Alzheimer Report 2009 London: Alzheimer's Disease International 2009
2. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ, Alzheimers Dement 2012 8 1 13 10.1016/j.jalz.2011.10.007 22265587
3. Alzheimer's disease is a synaptic failure. Selkoe DJ, Science 2002 298 789 791 10.1126/science.1074069 12399581 (Pubitemid 35231524)
4. Alzheimer's disease and the aging brain. Terry RD, J Geriatr Psychiatry Neurol 2006 19 125 128 10.1177/0891988706291079 16880353 (Pubitemid 44154851)
5. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. van Wijk N, Broersen LM, de Wilde MC, Hageman RJ, Groenendijk M, Sijben JW, Kamphuis PJ, J Alzheimers Dis 2014 38 459 479 23985420
6. Synapse formation and cognitive brain development: effect of docosahexaenoic acid and other dietary constituents. Wurtman RJ, Metabolism 2008 57 6 S10 18803968
7. Can nutrients prevent or delay onset of Alzheimer's disease? Kamphuis PJ, Scheltens P, J Alzheimers Dis 2010 20 765 775 20182021
8. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A, Alzheimers Dement 2010 6 1 10 e11 10.1016/j.jalz.2009.10.003 20129316
9. Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P, J Nutr Health Aging 2011 15 720 724 10.1007/s12603-011-0105-6 21968871
10. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ, J Alzheimers Dis 2012 31 225 236 22766770
11. Scales as outcome measures for Alzheimer's disease. Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, Stern Y, Alzheimers Dement 2009 5 324 339 10.1016/j.jalz.2009.05.667 19560103
12. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Folstein MF, Folstein SE, McHugh PR, J Psychiatr Res 1975 12 189 198 10.1016/0022-3956(75)90026-6 1202204
13. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841 (Pubitemid 14076461)
14. The short form of the Geriatric Depression Scale: a comparison with the 30-item form. Burke WJ, Roccaforte WH, Wengel SP, J Geriatr Psychiatry Neurol 1991 4 173 178 10.1177/089198879100400310 1953971
15. A new rating scale for Alzheimer's disease. Rosen WG, Mohs RC, Davis KL, Am J Psychiatry 1984 141 1356 1364 6496779
16. Wechsler D, Wechsler Memory Scale Manual Psychological Corp.: San Diego, CA 1987
17. The Concept Shifting Test: adult normative data. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J, Psychol Assess 2006 18 424 432 17154763 (Pubitemid 44950886)
18. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J, J Clin Exp Neuropsychol 2006 28 998 1009 10.1080/13803390591004428 16822738 (Pubitemid 44034738)
19. Lezak MD, Howieson DB, Loring DW, Neuropsychological Assessment New York: Oxford University Press 2004
20. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S, Alzheimer Dis Assoc Disord 1997 11 33 S39 9236950
21. The Clinical Dementia Rating (CDR): current version and scoring rules. Morris JC, Neurology 1993 43 2412 2414 (Pubitemid 23346995)
22. Clinical Dementia Rating (CDR). Berg L, Psychopharmacol Bull 1988 24 637 639 3249765 (Pubitemid 19054369)
23. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Doraiswamy PM, Kaiser L, Bieber F, Garman RL, Alzheimer Dis Assoc Disord 2001 15 174 183 10.1097/00002093-200110000-00003 11723368 (Pubitemid 33117033)
24. Use of phosphatide precursors to promote synaptogenesis. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH, Annu Rev Nutr 2009 29 59 87 10.1146/annurev-nutr- 080508-141059 19400698
25. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. Selkoe DJ, J Clin Invest 2002 110 1375 1381 12438432 (Pubitemid 35396905)
26. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R, Ann Neurol 1991 30 572 580 10.1002/ana.410300410 1789684
27. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH, Alzheimers Dement 2011 7 280 292 10.1016/j.jalz.2011.03.003 21514248
28. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. DeKosky ST, Scheff SW, Ann Neurol 1990 27 457 464 10.1002/ana.410270502 2360787 (Pubitemid 20149963)
29. Report of the task force on designing clinical trials in early (predementia) AD. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B, Neurology 2011 76 280 286 10.1212/WNL. 0b013e318207b1b9 21178097